Baseline patient characteristics
| Variable . | N (%*) or median (range) . |
|---|---|
| Total | 30 (100) |
| Age, y | 33 (20-69) |
| Sex | |
| Male | 16 (53) |
| Female | 14 (47) |
| Frontline therapy | |
| A(B)VD† | 24 (80) |
| BV-A(B)VD | 1 (3) |
| ABVE-PC | 1 (3) |
| BEACOPP‡ | 2 (7) |
| RCHOP/REPOCH | 2 (7) |
| Prior brentuximab exposure | 6 (20) |
| Prior nivolumab or pembrolizumab exposure | 6 (20) |
| Prior radiotherapy | 7 (23) |
| Conditioning regimen | |
| BEAM | 30 (100) |
| Risk factors | |
| Primary refractory disease | 17 (57) |
| Relapse within 12 mo | 5 (17) |
| Extranodal disease at relapse | 8 (27) |
| At least 1 of above 3 factors | 26 (87) |
| Residual disease after salvage | 3 (10) |
| B symptoms at relapse | 2 (7) |
| >1 salvage therapy | 5 (17) |
| At least 1 of above 6 factors | 27 (90) |
| At least 2 of above 6 factors | 12 (40) |
| Disease status at study entry (post-ASCT) | |
| Partial remission | 2 (7) |
| Complete remission | 28 (93) |
| Variable . | N (%*) or median (range) . |
|---|---|
| Total | 30 (100) |
| Age, y | 33 (20-69) |
| Sex | |
| Male | 16 (53) |
| Female | 14 (47) |
| Frontline therapy | |
| A(B)VD† | 24 (80) |
| BV-A(B)VD | 1 (3) |
| ABVE-PC | 1 (3) |
| BEACOPP‡ | 2 (7) |
| RCHOP/REPOCH | 2 (7) |
| Prior brentuximab exposure | 6 (20) |
| Prior nivolumab or pembrolizumab exposure | 6 (20) |
| Prior radiotherapy | 7 (23) |
| Conditioning regimen | |
| BEAM | 30 (100) |
| Risk factors | |
| Primary refractory disease | 17 (57) |
| Relapse within 12 mo | 5 (17) |
| Extranodal disease at relapse | 8 (27) |
| At least 1 of above 3 factors | 26 (87) |
| Residual disease after salvage | 3 (10) |
| B symptoms at relapse | 2 (7) |
| >1 salvage therapy | 5 (17) |
| At least 1 of above 6 factors | 27 (90) |
| At least 2 of above 6 factors | 12 (40) |
| Disease status at study entry (post-ASCT) | |
| Partial remission | 2 (7) |
| Complete remission | 28 (93) |
A(B)VD, doxorubicin, bleomycin, vinblastine, and dacarbazine; ABVE-PC, doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; BEAM, carmustine, etoposide, cytarabine, and melphalan; BV, brentuximab vedotin; RCHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; REPOCH, rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.
Percentages may not add to 100 because of rounding.
With rituximab in 1 patient.
Given after ABVD in 1 additional patient.